Survival Analysis of Lung Cancer Patients at Dr. Saiful Anwar Hospital
DOI:
https://doi.org/10.11594/jk-risk.03.3.2Keywords:
lung cancer, chemotherapy, survival rateAbstract
Background: Comprising 14% of all cancer, lung cancer is the main cause of cancer-related mortality worldwide. Previous studies showed various findings regarding the survival rate of lung cancer, and factors significantly correlated with survival rate in lung cancer patients.
Aim: This research aims to identify the profile and survival rate of lung cancer patients receiving chemotherapy in Saiful Anwar General Hospital from 2018 to 2020.
Methods: This cohort retrospective study used medical records of patients diagnosed with lung cancer who underwent chemotherapy from 2018 to 2020. Data analysis was done using the Mantel Cox log rank test. Survival data shown as progression free survival (PFS) and overall survival (OS) were shown using Kaplan-Meier curves.
Results: Subjects were largely male (73,2%). Adenocarcinoma is the most often type of lung cancer found (59,8%) with wild type EGFR mutation being the most prevalent (20,6%). Carboplatin – Paclitaxel is the most widely used chemotherapy regimen (54,6%). Survival analysis showed a significant correlation between age, OS, and PFS (p < 0,05)
Conclusion: Various factors such as gender, cancer cell type, EGFR mutation, and chemotherapy regimen were not found to be related to survival rate in lung cancer patients. A significant correlation between age and survival rate showed potential in utilizing age as a predictor of survival rate in lung cancer patients.
Downloads
References
Barta JA, Powell CA, Wisnivesky JP. Global Epi-demiology of Lung Cancer. Annals of Global Health. 2019;85(1):8.
Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Con-temp Oncol (Pozn). 2021;25(1):45–52.
KPKN. Pedoman Nasional Pelayanan Kedokteran Kanker Paru. 2017;
Pratiwi SD. Profil Tumor Paru tahun 2017 pada Instalasi Rawat Inap 1 RSUD dr. Saiful Anwar Malang. 2020;
ÖNAL Ö, KOÇER M, EROĞLU HN, YILMAZ SD, EROĞLU İ, KARADOĞAN D. Survival analysis and factors affecting survival in patients who presented to the medical oncology unit with non-small cell lung cancer. Turk J Med Sci. 2020 Dec 17;50(8):1838–50.
Liu C, Ma M, Zhou X, Zhang Z, Guo Y. Multivari-ate analysis of prognostic factors in patients with lung cancer. Frontiers in Oncology [Inter-net]. 2023 [cited 2023 Jul 13];13. Available from: https://www.frontiersin.org/articles/10.3389/fonc.2023.1022862
Torrente M, Sousa PA, Guerreiro GR, Franco F, Hernández R, Parejo C, et al. Clinical factors in-fluencing long-term survival in a real-life co-hort of early stage non-small-cell lung cancer patients in Spain. Frontiers in Oncology [Inter-net]. 2023 [cited 2023 Jul 13];13. Available from: https://www.frontiersin.org/articles/10.3389/fonc.2023.1074337
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
Hong H, Wang Q, Li J, Liu H, Meng X, Zhang H. Aging, Cancer and Immunity. J Cancer. 2019 Jun 2;10(13):3021–7.
Zannah SJ, Murti IS, Sulistiawati S. Hubungan Usia dengan Stadium Saat Diagnosis Penderita Kanker Kolorektal di RSUD Abdul Wahab Sjah-ranie Samarinda: Relationship of Age and Sta-dium when Diagnosed of Cholorectal Cancer at RSUD Abdul Wahab Sjahranie Samarinda. Jurnal Sains dan Kesehatan. 2021 Oct 31;3(5):701–5.
Ahmed T, Lycan T, Dothard A, Ehrlichman P, Ruiz J, Farris M, et al. Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non—Small-Cell Lung Cancer. Clin Lung Cancer. 2020 Jul;21(4):e286–93.
McLean AEB, Barnes DJ, Troy LK. Diagnosing Lung Cancer: The Complexities of Obtaining a Tissue Diagnosis in the Era of Minimally Inva-sive and Personalised Medicine. J Clin Med. 2018 Jun 29;7(7):163.
Magios N, Bozorgmehr F, Volckmar AL, Kazdal D, Kirchner M, Herth FJ, et al. Real-world im-plementation of sequential targeted therapies for EGFR-mutated lung cancer. Ther Adv Med Oncol. 2021;13:1758835921996509.
Miyawaki E, Kenmotsu H, Shintani Y, Sekine I, Shukuya T, Takayama K, et al. Efficacy of plati-num agents for stage III non-small-cell lung cancer following platinum-based chemoradio-therapy: a retrospective study. BMC Cancer. 2022 Mar 29;22(1):342.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges and earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
